GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 in IPF
LA JOLLA, Calif., June 18, 2026 GRI Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
LA JOLLA, Calif., June 18, 2026 GRI Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
INGELHEIM, Germany, June 18, 2026 Boehringer Ingelheim has announced new long-term survival modeling analyses from its pivotal Phase III...
NEW YORK, N.Y., June 16, 2026 The Clinical Trials on Alzheimer’s Disease (CTAD) Conference and the Alzheimer’s Drug Discovery...
BRUSSELS, Belgium, June 17, 2026 UCB has announced the publication of two significant peer-reviewed studies in Brain Communications demonstrating...
DUBLIN, Ireland, June 16, 2026 Jazz Pharmaceuticals plc has unveiled extensive late-breaking research at SLEEP 2026, presenting 11 new...
SAN RAFAEL, Calif., June 16, 2026 BioMarin Pharmaceutical Inc. announced new clinical findings from its approved therapy VOXZOGO® (vosoritide)...
SAN DIEGO, June 15, 2026 Neurocrine Biosciences has unveiled new two-year data from its Phase 3 CAHtalyst® Adult study,...
SAN DIEGO, June 15, 2026 Neurocrine Biosciences has presented new two-year data from its Phase 3 CAHtalyst® Pediatric study,...
Hong Kong, Shanghai & Florham Park, N.J., June 12, 2026 HUTCHMED (China) Limited announced positive results from the Phase...
BOSTON, Mass., June 11, 2026 JW Pharmaceutical announced new preclinical findings and its global development strategy for DDC-02, an...
